Compare LEE & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | CCCC |
|---|---|---|
| Founded | 1890 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.1M | 185.1M |
| IPO Year | 2025 | 2020 |
| Metric | LEE | CCCC |
|---|---|---|
| Price | $8.72 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 34.3K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $543,955,000.00 | $35,947,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $3.34 | $1.21 |
| 52 Week High | $9.97 | $3.82 |
| Indicator | LEE | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 58.18 |
| Support Level | $8.07 | $2.30 |
| Resistance Level | $9.40 | $3.82 |
| Average True Range (ATR) | 0.47 | 0.24 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 83.50 | 75.71 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.